Rhizen Pharmaceuticals SA and Incozen Therapeutics Pvt. Ltd. have disclosed salts of NAD+ ADP-ribosyltransferase poly [ADP-ribose] polymerase (PARP) inhibitors reported to be useful for the treatment of cancer, bone, cardiovascular, immunological, inflammatory and respiratory disorders, metabolic diseases and thrombosis.